OCUL OCULAR THERAPEUTIX INC revenue, earnings and financials

For the quarter ended June 30, 2026, OCULAR THERAPEUTIX INC reported revenue of $13.5M (up 0.1% from a year earlier), net income of −$78.8M and diluted EPS of −$0.35; over the last four quarters revenue was $52.1M and net income −$301M; for the fiscal year ended December 2025 revenue was $52.0M, down 18.5% on the year before.

OCUL annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $52.0M, gross profit n/a, operating income −$270M, net income −$266M (margin -511.9%), EPS −$1.42
• Fiscal year ended Dec 2024: revenue $63.7M, gross profit n/a, operating income −$172M, net income −$194M (margin -303.7%), EPS −$1.22
• Fiscal year ended Dec 2023: revenue $58.4M, gross profit n/a, operating income −$82.4M, net income −$80.7M (margin -138.1%), EPS −$1.02
• Fiscal year ended Dec 2022: revenue $51.5M, gross profit n/a, operating income −$78.7M, net income −$71.0M (margin -138.0%), EPS −$0.97
• Fiscal year ended Dec 2021: revenue $43.5M, gross profit n/a, operating income −$78.0M, net income −$6.55M (margin -15.1%), EPS −$0.98

OCUL quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $13.5M (up 0.1% year over year), net income −$78.8M, EPS −$0.35
• Quarter ended Mar 31, 2026: revenue $10.8M (up 0.8% year over year), net income −$88.6M, EPS −$0.40
• Quarter ended Dec 31, 2025 (from the annual report): revenue $13.3M (down 22.4% year over year), net income −$64.7M, EPS −$0.27
• Quarter ended Sep 30, 2025: revenue $14.5M (down 5.7% year over year), net income −$69.4M, EPS −$0.38
• Quarter ended Jun 30, 2025: revenue $13.5M (down 18.1% year over year), net income −$67.8M, EPS −$0.39
• Quarter ended Mar 31, 2025: revenue $10.7M (down 27.6% year over year), net income −$64.1M, EPS −$0.38
• Quarter ended Dec 31, 2024 (from the annual report): revenue $17.1M (up 15.4% year over year), net income −$48.4M, EPS −$0.25
• Quarter ended Sep 30, 2024: revenue $15.4M (up 2.3% year over year), net income −$36.5M, EPS −$0.22
• Quarter ended Jun 30, 2024: revenue $16.4M (up 8.3% year over year), net income −$43.8M, EPS −$0.26
• Quarter ended Mar 31, 2024: revenue $14.8M (up 10.5% year over year), net income −$64.8M, EPS −$0.49
• Quarter ended Dec 31, 2023 (from the annual report): revenue $14.8M (up 5.2% year over year), net income −$29.2M, EPS −$0.12
• Quarter ended Sep 30, 2023: revenue $15.1M (up 26.0% year over year), net income −$516K, EPS −$0.25
• Quarter ended Jun 30, 2023: revenue $15.2M (up 23.8% year over year), net income −$20.7M, EPS −$0.26
• Quarter ended Mar 31, 2023: revenue $13.4M (up 1.4% year over year), net income −$30.3M, EPS −$0.39
• Quarter ended Dec 31, 2022 (from the annual report): revenue $14.1M (up 14.4% year over year), net income −$15.5M, EPS −$0.19
• Quarter ended Sep 30, 2022: revenue $12.0M (down 1.5% year over year), net income −$24.2M, EPS −$0.31
• Quarter ended Jun 30, 2022: revenue $12.3M (up 4.7% year over year), net income −$18.8M, EPS −$0.25
• Quarter ended Mar 31, 2022: revenue $13.2M (up 79.6% year over year), net income −$12.5M, EPS −$0.22
• Quarter ended Dec 31, 2021 (from the annual report): revenue $12.3M, net income −$3.85M, EPS −$0.26
• Quarter ended Sep 30, 2021: revenue $12.2M, net income $2.66M, EPS −$0.23

OCUL cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$205M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$135M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$70.2M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$59.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$65.6M, share buybacks n/a

OCUL balance sheet

• Jun 30, 2026: cash $599M, total assets $671M, total liabilities $151M, shareholders' equity $520M
• Mar 31, 2026: cash $667M, total assets $733M, total liabilities $151M, shareholders' equity $582M
• Dec 31, 2025: cash $737M, total assets $808M, total liabilities $154M, shareholders' equity $654M
• Sep 30, 2025: cash $345M, total assets $411M, total liabilities $153M, shareholders' equity $258M
• Jun 30, 2025: cash $391M, total assets $451M, total liabilities $145M, shareholders' equity $306M
• Mar 31, 2025: cash $350M, total assets $406M, total liabilities $140M, shareholders' equity $266M
• Dec 31, 2024: cash $392M, total assets $458M, total liabilities $143M, shareholders' equity $315M
• Sep 30, 2024: cash $427M, total assets $490M, total liabilities $138M, shareholders' equity $352M

What is OCUL's revenue?

OCULAR THERAPEUTIX INC reported $52.1M of revenue over its last four quarters, through June 30, 2026.

Is OCUL profitable?

No. OCULAR THERAPEUTIX INC lost $301M over the last four quarters.

What is OCUL's EPS?

Diluted earnings per share over the last four quarters were −$1.40; −$0.35 in the latest quarter.

OCUL ownership and insider trades · All stocks